Snuderl M.

Snuderl M. is a prominent researcher at the German Cancer Research Center (DKFZ) in Heidelberg, Germany, specializing in neuropathology and neuro-oncology. As a key contributor to the cIMPACT-NOW consortium, they have co-authored multiple influential updates (9, 10, and 11) that shape the World Health Organization's classification of central nervous system tumors. Their research primarily focuses on molecular diagnostics, DNA methylation profiling, and the genomic characterization of brain tumors including meningiomas, astrocytomas, and medulloblastomas.

Snuderl M.'s work bridges laboratory research with clinical applications, developing diagnostic tools that improve tumor classification and patient outcomes. They have made significant contributions to understanding TERT promoter mutations in meningioma prognosis, BAP1-altered meningioma biology, and the molecular signatures of rare CNS tumors like pleomorphic xanthoastrocytoma and intraparenchymal schwannomas. Their research has been published in leading neuro-oncology journals including Neuro-Oncology, Acta Neuropathologica, and The Lancet Oncology.

Their publication record demonstrates expertise in translating complex molecular data into clinically actionable diagnostic criteria. Recent work has focused on refining classification systems for IDH-mutant astrocytomas, H3 G34-mutant diffuse hemispheric gliomas, and NTRK fusion-driven CNS tumors. The research shows consistent emphasis on identifying molecular biomarkers that predict clinical behavior and therapeutic response.

• cIMPACT-NOW Consortium Member (key contributor to WHO CNS tumor classification updates)
• Developer of molecular diagnostic approaches for CNS tumors
• Expert in DNA methylation profiling applications for neuro-oncology

Snuderl M. collaborates extensively with international neuro-oncology centers, participating in multi-institutional cohort studies that analyze hundreds of tumor samples. Their work supports the integration of molecular diagnostics into routine neuropathology practice, improving precision in tumor classification and patient management. Current research directions include refining risk stratification systems for pediatric CNS tumors and developing proteomic approaches to identify therapy-resistant tumor subgroups.